Chapter 73

Depression

Camilla S. Hanson

Camilla S. Hanson

Sydney School of Public Health University of Sydney, Sydney, NSW, Australia

Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia

Search for more papers by this author
Charlotte Logeman

Charlotte Logeman

Sydney School of Public Health University of Sydney, Sydney, NSW, Australia

Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia

Search for more papers by this author
Mary Amanda Dew

Mary Amanda Dew

Department of Psychiatry, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA, USA

Search for more papers by this author
Suetonia C. Palmer

Suetonia C. Palmer

Department of Medicine, University of Otago Christchurch, Christchurch, Canterbury, New Zealand

Search for more papers by this author
First published: 18 November 2022

Summary

Major depressive disorder (MDD) is common among patients with chronic kidney disease (CKD) and end-stage kidney disease, more so than in other chronic conditions, and is associated with a range of adverse clinical outcomes. It is not known whether depression in patients with CKD is different from depression that is seen in individuals without a comorbid chronic medical condition, and in particular whether depressive symptom severity and the efficacy of treatment is modified by decrements in kidney function. Studies of patients with CKD and end-stage kidney disease have identified vastly different estimates of the prevalence of depression. Compared to studies assessing depression among hemodialysis populations, there are limited studies among individuals receiving peritoneal dialysis and the available studies involve relatively small samples of patients. The studies assessing the prevalence of depression among kidney transplant populations are predominately small single-center samples.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.